@phdthesis{Mambretti2015,
  author    = {Mambretti, Egle Maria},
  title     = {Opioid receptors as therapeutic targets for nociceptor specific regional analgesia},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-128866},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {Opioids have been, since centuries, the gold standard for pain treatment and relief. They exert their effects after binding to opioid receptors (OP) that are expressed and functional in the central (CNS) and peripheral nervous system (PNS). As their systemic application has many side effects, including sedation and respiratory depression, a peripheral application of opioids and selective targeting of µ-OP (MOP) in nociceptive axons would be extremely beneficial. MOP presence and function has been conclusively demonstrated at nerve terminals; however it is still controversial whether functional MOPs are available on the membrane of peripheral nociceptive axons to mediate opioid-induced antinociception. While under pathologic conditions (i.e. nerve injury) exogenous as well as endogenous MOP agonists applied at the damaged nerve can elicit potent antinociception or anti-allodynia, under physiological conditions no antinociception was seen in rats. This could be caused by either a lack of functional opioid receptors in the axonal membranes or by the inability of injected opioids to cross the intact perineurial barrier and to reach nociceptors. Previous behavioral test results showed an antinociceptive effect (up to 5h) following perisciatic application of the hydrophilic DAMGO (MOP agonist) if coinjected with hypertonic saline solution (HTS; 10\% NaCl), a treatment suited to open the perineural barrier. The effect was inhibited by naloxone, a MOP antagonist, documenting its specific action via MOP. Fentanyl, a lipophilic opioid, elicited an effect, which was enhanced by HTS treatment, indicating that HTS may act not only on the barrier but also directly on axonal MOP presence and/or functionality. To provide a basis for testing this hypothesis, the present work was designed to study the axonal localization of MOP in experimental animals under different conditions using molecular and morphological methods. Initially four different commercial antibodies were tested for MOP detection. Immunoreactions with these antibodies specifically detected MOP in the hippocampus and in amygdala, while in the peripheral nervous system the reactions showed varying labeling patterns pointing towards less specificity with low signal-to-noise ratio. Double labelling with calcitonin gene related peptide (CGRP), a neuropeptide expressed in sensory fibers, with the non-compacted myelin marker S100 or with the neuronal marker PGP9.5 documented significant immunoreaction signals outside sensory nerve fibers. Therefore, none of these antibodies appeared suitable. Taking advantage of a new commercial monoclonal rabbit antibody (RabMAb) and of genetically modified mice in which the fluorescent protein mcherry was inserted in the C-tail of MOP (MOP-mcherry knock-in mice), MOP fusion protein expression in rat and mouse CGRP+ sciatic nerve fibers and fiber bundles was confirmed by immunofluorescence labeling. Immunoelectron microscopic analysis indicated MOP/MOP-mcherry-localization in the cytoplasm and the membranes of unmyelinated axons organized in Remak bundles. Both antibodies detected bands of appropriate size in Western Blot in the CNS and additional larger bands in the PNS. Quantitative analyses 60 min after HTS-treatment revealed no change in MOP mRNA in the sciatic nerve and DRG as well as no change in MOP immunoreactivity in the sciatic nerve. Thus, the opioid-induced long lasting antinociception enhanced by perisciatic injection of HTS were not due to a sustained increased MOP expression or content in sensory, putative nociceptive axons. In summary, the current study succeeded to unequivocally document the presence of MOP protein in intact sensory axons of rat and mouse sciatic nerve. Thus, axonal MOPs may indeed mediate antinociceptive opioid effects observed in behavioral studies in naive animals possibly via activation of potassium or calcium channels. As HTS treatment does not lead to a sustained increase in axonal MOP protein or MOP mRNA expression, other mechanisms might enhance MOP function, including inhibition of MOP recycling or changes in functional coupling. Future studies should further explore the axonal mechanisms of antinociception by opioids and enhancing treatments.},
  subject      = {Opioide},
  language  = {en}
}
@phdthesis{Subbarayal2015,
  author    = {Subbarayal, Prema},
  title     = {The role of human Ephrin receptor tyrosine kinase A2 (EphA2) in Chlamydia trachomatis infection},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-114778},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2015},
  abstract  = {Chlamydia trachomatis (Ctr), an obligate intracellular gram negative human pathogen, causes sexually transmitted diseases and acquired blindness in developing countries. The infectious elementary bodies (EB) of Ctr involved in adherence and invasion processes are critical for chlamydial infectivity and subsequent pathogenesis which requires cooperative interaction of several host cell factors. Few receptors have been known for this early event, yet the molecular mechanism of these receptors involvement throughout Ctr infection is not known. Chlamydial inclusion membrane serves as a signaling platform that coordinates Chlamydia-host cell interaction which encouraged me to look for host cell factors that associates with the inclusion membrane, using proteome analysis. The role of these factors in chlamydial replication was analyzed by RNA interference (RNAi) (in collaboration with AG Thomas Meyer). Interestingly, EphrinA2 receptor (EphA2), a cell surface tyrosine kinase receptor, implicated in many cancers, was identified as one of the potential candidates. Due to the presence of EphA2 in the Ctr inclusion proteome data, I investigated the role of EphA2 in Ctr infection. EphA2 was identified as a direct interacting receptor for adherence and entry of C. trachomatis. Pre-incubation of Ctr-EB with recombinant human EphA2, knockdown of EphA2 by siRNA, pretreatment of cells with anti-EphA2 antibodies or the tyrosine kinase inhibitor dasatinib significantly reduced Ctr infection. This marked reduction of Ctr infection was seen with both epithelial and endothelial cells used in this study. Ctr activates EphA2 upon infection and invades the cell together with the activated EphA2 receptor that interacts and activates PI3K survival signal, promoting chlamydial replication. EphA2 upregulation during infection is associated with Ctr inclusion membrane inside the cell and are prevented being translocated to the cell surface. Ephrins are natural ligands for Ephrin receptors that repress the activation of the PI3K/Akt pathway in a process called reverse signaling. Purified Ephrin-A1, a ligand of EphA2, strongly interferes with chlamydial infection and normal development, supporting the central role of these receptors in Chlamydia infection. Overexpression of full length EphA2, but not the mutant form lacking the intracellular cytoplasmic domain, enhanced PI3K activation and Ctr infection. Ctr infection induces EphA2 upregulation and is mediated by activation of ERK signaling pathway. Interfering with EphA2 upregulation sensitizes Ctr-infected cells to apoptosis induced by tumor necrosis factor-alpha (TNF-α) suggesting the importance of intracellular EphA2 signaling. Collectively, these results revealed the first Ephrin receptor "EphA2" that functions in promoting chlamydial infection. In addition, the engagement of a cell surface receptor at the inclusion membrane is a new mechanism how Chlamydia subverts the host cell and induces apoptosis resistance. By applying the natural ligand Ephrin-A1 and targeting EphA2 offers a promising new approach to interfere with Chlamydia infection. Thus, the work provides the evidence for a host cell surface tyrosine kinase receptor that is exploited for invasion as well as for receptor-mediated intracellular signaling to facilitate the chlamydial replication.},
  subject      = {Chlamydia trachomatis},
  language  = {en}
}